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Background: Heat Shock Transcription Factor 1 (HSF1) is activated under stress conditions. In turn, it induces
expression of Heat Shock Proteins (HSPs), which are well-known regulators of protein homeostasis. Elevated levels
of HSF1 and HSPs were observed in many types of tumors. The aim of the present study was to determine whether
HSF1 could have an effect on the survival of cancer cells treated with chemotherapeutic cytotoxic agents.
Methods: We constructed mouse (B16F10) and human (1205Lu, WM793B) melanoma cells overexpressing full or
mutant form of human HSF1: a constitutively active one with a deletion in regulatory domain or a dominant negative
one with a deletion in the activation domain. The impact of different forms of HSF1 on the expression of HSP and ABC
genes was studied by RT-PCR and Western blotting. Cell cultures were treated with increasing amounts of doxorubicin,
paclitaxel, cisplatin, vinblastine or bortezomib. Cell viability was determined by MTT, and IC50 was calculated. Cellular
accumulation of fluorescent dyes and side population cells were studied using flow cytometry.
Results: Cells overexpressing HSF1 and characterized by increased HSPs accumulation were more resistant to
doxorubicin or paclitaxel, but not to cisplatin, vinblastine or bortezomib. This resistance correlated with the enhanced
efflux of fluorescent dyes and the increased number of side population cells. The expression of constitutively active
mutant HSF1, also resulting in HSPs overproduction, did not reduce the sensitivity of melanoma cells to drugs,
unlike in the case of dominant negative form expression. Cells overexpressing a full or dominant negative form
of HSF1, but not a constitutively active one, had higher transcription levels of ABC genes when compared to
control cells.
Conclusions: HSF1 overexpression facilitates the survival of melanoma cells treated with doxorubicin or
paclitaxel. However, HSF1-mediated chemoresistance is not dependent on HSPs accumulation but on an
increased potential for drug efflux by ABC transporters. Direct transcriptional activity of HSF1 is not necessary for
increased expression of ABC genes, which is probably mediated by HSF1 regulatory domain.
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HSF1-dependent stress response is an adaptive mechan-
ism which enhances the survival of somatic cells facing di-
verse arrays of environmental and physiological challenges
(such as heat shock, ischemic injury, neurodegeneration,
and others) [1,2]. Activation of HSF1 results in induced
expression of a set of highly conserved proteins, known as
heat shock proteins (HSPs). HSPs act as molecular chape-* Correspondence: nvydra@yahoo.co.uk
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reproduction in any medium, provided the orrones by assisting protein folding during their synthesis or
repair under proteotoxic conditions. Mammalian HSPs
are classified according to molecular size into several fam-
ilies including HSPH (HSP110), HSPC (HSP90), HSPA
(HSP70), HSPD (HSP60), and HSPB (small HSPs, sHSPs).
Each gene family includes members that are constitutively
expressed, inducibly regulated, and/or targeted to different
cellular compartments [3].
The primary role of HSF1 in cells is associated with the
regulation of HSPs expression in response to heat shock
or other stress conditions. Moreover, there is some evi-td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with development, growth and fertility [4-7].
Furthermore, HSF1 facilitates cell survival upon imbal-
anced cell signaling associated with neoplastic transform-
ation. Convincing evidence of HSF1 involvement in
carcinogenesis has emerged from data gathered from a
murine tumor model. Namely, lack of HSF1 expression
protected mice against tumorigenesis in a chemically-
induced skin carcinogenesis model and in a genetic model
driven by a clinically relevant oncogenic mutation in p53
(p53R172H) [8]. The role of HSF1 in carcinogenesis in-
cludes protecting cancer cells from programmed cell
death, overriding cell cycle checkpoints and enhancing
metastasis [9-11]. HSF1 also orchestrates a broad network
of core cellular functions associated with proliferation,
survival, protein synthesis and glucose metabolism, thus
enhancing oncogenic transformation [8,9].
Activation of HSF1-dependent stress response, a cyto-
protective mechanism, may greatly influence develop-
ment of an adaptive and protective phenotype in cancer
cells subjected to anticancer agents. Elevated expression
of HSPs (e.g., HSP90, HSP70, HSP27) has been reported
in many types of human malignancies and was linked to
cancer resistance to apoptosis induced by chemotherapeu-
tic agents [12-14]. The antiapoptotic function of HSPs was
shown for monoblastoid U937 cells and murine fibrosar-
coma WEHI-S cells treated with actinomycin-D, camp-
tothecin and etoposide [15] as well as rat brain tumor
cells treated with vincristine [16]. In addition, HSP-
independent mechanism may be involved in HSF1 regu-
lated resistance of cancer cells to chemotherapeutics.
HSF1-binding elements were found in ABCB1 (MDR1)
gene promoter coding for P-glycoprotein (P-gp), an
energy-dependent drug efflux pump [17,18].
In this study, we established mouse and human melan-
oma cells overexpressing hHSF1 to study the effect of
HSF1 on the survival of cancer cells treated with cyto-
toxic agents used in chemotherapy. Here, we generated
melanoma cells with different mutant forms of human
HSF1, leading either to constitutive HSPs activation
(transcriptionally active) or lacking the ability to activate
HSPs expression (dominant-negative). We also obtained
mouse melanoma B16F10 cells with a silenced HSF1 ex-
pression. We were thus able to evaluate the contribution
of HSF1 and HSPs level in the development of drug re-
sistance by melanoma cells.
Methods
Cell lines and cell culture
Melanoma cell lines, B16F10 (mouse), WM793B and
1205Lu (human), were obtained from American Type
Cell Culture Collection (ATCC, Manassas, VA). Cells
were routinely cultured according to ATCC protocol.
Doubling time for B16F10 cells is approximately 24 h,for WM793B and 1205Lu – approximately 48 h. Heat
shock was performed by placing plates with logarithmic-
ally growing cells in an incubator (Heraeus), at 42°C for
1 hour. For transcriptional studies, cells were allowed to
recover at 37°C for 30 minutes or for protein studies
were lysed immediately after heat shock or after 6-hour
recovery.
DNA constructs
Human HSF1 (hHSF1) coding sequence (Accession no.
NM_005526.2) was amplified by PCR using cDNA from
WM793B cells as a template; the sequence recognized
by HindIII restriction enzyme was introduced into primers.
HSF1 cDNA fragment was inserted downstream of the hu-
man β-actin promoter into the pHβApr-1-neo expression
vector. The hHSF1ΔRD construct containing a constitu-
tively active form of human HSF1 (aHSF1; with 221–315
amino acid deletion) driven by the human β-actin pro-
moter in the pHβApr-1-neo expression vector, was kindly
provided by Dr. A. Nakai [6]. A plasmid containing domin-
ant negative human HSF1 (hHSF1-DN; with deletion of
amino acids 453–523; [19]) was constructed by PCR-
mediated site-directed mutagenesis consisting of two-step
PCR, using two overlapping internal primers at the muta-
genic site and two outer general primers each flanked by
HindIII site. The internal primers were as follows: forward
5′-GAGCCCCCCAGGCCTCCCAAGGACCCCACTGTC
TTC; reverse 5′-GAAGACAGTGGGGTCCTTGGGAGG
CCTGGGGGGCTG. The mutant hHSF1-DN cDNA frag-
ment was inserted downstream of the human β-actin
promoter into the pHβApr-1-neo expression vector. The
hHSF1, aHSF1, hHSF1-DN sequences were also cloned
into the pLNCX2 retrovirus expression vector down-
stream of the CMV promoter (Clontech). Nucleotide
sequence of all constructs was verified by DNA sequen-
cing. Schematic diagram of a structure of analyzed hHSF1
proteins is shown in Additional file 1: Figure S1.
Stable transfections
Mouse melanoma B16F10 cells were transfected with
vectors containing hHSF1, aHSF1, and hHSF1-DN cDNA
using Lipofectamine™2000 according to the manufac-
turer’s protocol (Life Technologies). To select clones that
stably express the integrated vector, cells were cultured for
7 days with G-418 (1 mg/ml, Life Technologies). Then,
cells were seeded on a 96-well plate (1 cell/well) in the
presence of G-418. When colonies were formed, 7–11 in-
dividual clones were collected for each construct. Clones
expressing the introduced HSF1 (as estimated by Western
blotting) were pooled together for further experiments.
Stably transfected human melanoma WM793B and
1205Lu cells were obtained by retroviral gene transfer of
hHSF1, aHSF1, hHSF1-DN cDNA cloned in the pLNCX2
vector according to the manufacturer’s protocol (Clontech
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of polybrene (8 μg/ml) and selected in the presence of
G-418 (200 μg/ml - WM793B cells, and 400 μg/ml -
1205Lu cells).
Generation of HSF1-shRNA vectors
The shRNA target sequence for mouse HSF1 was selected
using the RNAi Target Sequence Selector (Clontech) and
according to a previous report [8]. The target sequences
were: HSF1-1 (1856–1876, NM_008296.2) - 5′ GCTGCA-
TACCTGCTGCCTTTA; and HSF1-2 (341–359, NM_008
296.2) - 5′AGCACAACAACATGGCTAG. Sense and anti-
sense oligonucleotides were annealed and inserted into the
pRNAi-Ready-Siren-RetroQ vector (Clontech) at BamHI/
EcoRI site. Infectious retroviruses were generated by trans-
fecting DNA into PT67 cells and virus-containing super-
natant was collected. Mouse melanoma B16F10 cells were
transduced with retroviruses containing HSF1 shRNAs
and selected using a medium supplemented with 1 μg/ml
puromycin (Life Technologies).
RNA isolation and RT-PCR
Extraction of total RNA, purification from DNA contam-
ination, synthesis of cDNA and RT-PCR were performed
as described in [20]. For RT-PCR 1–2 μl of cDNA tem-
plate was used and 25–35 cycles were applied depending
on the primers set. Quantitative RT-PCR was performed
using a Bio-Rad CFX 96TM Real-Time PCR Detection
System. A total of 5 pmoles of forward and reverse
primers, cDNA template were added to the Real-Time 2×
PCR Master Mix SYBR A (A&A Biotechnology, Gdynia,
Poland). Primers used in the analyses are listed in
Additional file 2: Table S2.
Protein extraction and Western blotting
Whole cell extracts were prepared using RIPA buffer.
Proteins (25 μg) were separated on 8-10% SDS-PAGE
gels and blotted to 0.45-μm pore nitrocellulose filter
(Millipore) [21]. Primary antibodies against HSF1 (rabbit
polyclonal, ADI-SPA-901, Enzo Life Sciences), HSP70
(mouse monoclonal, ADI-SPA-810, Enzo Life Sciences),
HSP25 (rabbit polyclonal, ADI-SPA-801, Enzo Life Sci-
ences), HSP105 (rabbit polyclonal, 3390–100, BioVision),
or actin (mouse monoclonal, clone C4, MAB1501, Millipore)
were used. The primary antibody was detected by appro-
priate secondary antibody conjugated with horseradish
peroxidase (ThermoScientific) and visualized by ECL kit
(ThermoScientific).
Treatment of cells with cytotoxic drugs and MTT assay
Mouse melanoma cells (1.5 × 103/well) or human mel-
anoma cells (4 × 103/well) were seeded in 96-well plates
and allowed to attach overnight. Cytotoxic agents: doxo-
rubicin (5, 10, 20, 40, 80 ng/ml), paclitaxel (5, 10, 20, 40,80 nM), vinblastin (1, 2, 4, 8, 16 nM), cisplatin (2, 4, 8,
16 μM) and bortezomib (2.5, 5, 10, 20 nM) were applied
for 48 hours (B16F10 cells) or for 72 h (WM793B and
1205Lu cells). Cell viability was determined by MTT
assay, as described in [22]. The absorbance (λ = 570 nm)
was read using Synergy 2 microplate reader (Biotek).
Relative survival was determined using the formula: via-
bility (%) = (cytotoxic agent treated-blank)/(untreated-
blank)*100. All experiments were performed at least in
triplicate.
Assay for the fluorescent dyes efflux
Cells suspended in phenol-free medium supplemented
with 0.5% FBS (PAA) in polystyrene tubes were incu-
bated for 30 minutes in a 37°C incubator with (i) doxo-
rubicin (1 μg/ml; 5 × 105 cells) or (ii) eFluxx-ID™ Green
Detection Reagent (Enzo Life Sciences) (2.5 × 105 cells).
Next, cells were washed, resuspended in PBS, and ana-
lyzed using a FACSCanto cytometer (Becton Dickinson).
Dye concentration and treatment exposure times were
established experimentally to obtain the best signal-to-
noise ratio.
Side population analysis
Cells were stained according to Goodell’s protocol [23].
Briefly, cells at 1 × 106/ml were suspended in prewarmed
phenol-free DMEM (Sigma-Aldrich) with 2% FBS. Hoechst
33342 (Sigma-Aldrich) was added to the final concen-
tration of 5 μg/ml in the presence or absence of verap-
amil (50 μg/ml; Sigma-Aldrich). Cells were incubated
at 37°C for 90 min with intermittent shaking. At the
end of incubation, cells were washed with phenol-free
DMEM, centrifuged at 4°C, and resuspended in ice-cold
PBS. Propidium iodide (Sigma-Aldrich) was added to
cells to gate viable cells. Analyses were performed using
FACSAria III apparatus (Becton Dickinson). The Hoechst
33342 dye was excited at 357 nm and its fluorescence was
dual-wavelength analyzed (blue, 402–446 nm; red, 650–
670 nm).
Statistical analysis
The data were analyzed by Student’s t-test. A p-value
of <0.05 was considered statistically significant.
Results
Overexpression of HSF1 in melanoma cells results in
enhanced survival of cells treated with doxorubicin
To determine whether the elevated expression of HSF1
could affect cell response to cytotoxic drugs we established
mouse (B16F10) and human (WM793B and 1205Lu) mel-
anoma cells overexpressing the full form of the human
HSF1 (hHSF1). Such modified cells were first character-
ized in the context of HSF1 and HSPs expression at
physiological and elevated temperature (heat shock) and
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(Neo). We established that HSF1 expression was signifi-
cantly elevated in hHSF1-overexpressing cells. Moreover,
the presence of extra copies of HSF1 in human cells re-
sulted in enhanced expression of inducible HSP70 (HSPA1)
already at physiological temperature, and which was visible
at both mRNA and protein levels (Figure 1A,B). Although
HSPA1 expression was not observed at physiological
temperature in mouse B16F10 cells overexpressing hHSF1,
the transcription of other HSF1-dependent genes (Hsph1,
Hspb1) was detected in those cells (Figure 1A). Hence,
overexpression of the human HSF1 was sufficient toFigure 1 Overexpression of HSF1 enhances doxorubicin resistance of
mouse (B16F10), and human (WM793B and 1205Lu) cells either with stably
the full form of human HSF1 (hHSF1). Where indicated, cells were subjecte
for 30 minutes. B. Western blot detection of HSF1 and HSPs in cells modifi
HSPs were detected after a 6-hour recovery. C. Viability of cells treated with
(WM793B and 1205Lu). Results of the MTT assay are shown in relation to th
experiments are presented (asterisks indicate p < 0.05).activate some HSP genes in mouse and human melan-
oma cells in heat shock-independent manner.
Next, control and hHSF1-overexpressing mouse and hu-
man melanoma cells were treated with increasing con-
centrations of cytotoxic agents: doxorubicin, vinblastine,
paclitaxel, cisplatin or bortezomib for the time period of
two cell divisions. Then, cell viability was determined by
the MTT assay, and IC50 was calculated. Melanoma cells
overexpressing hHSF1 showed an enhanced viability after
doxorubicin (Figure 1C, Table 1) as well as paclitaxel treat-
ments (Table 1) in comparison to unmodified or Neo con-
trol cells. The IC50 value for doxorubicin or paclitaxel inmelanoma cells. A. Detection of HSF1 and HSP gene transcripts in
introduced empty vector (Neo) /control/ or with a vector encoding
d to heat shock (HS) for 1 h at 42°C with subsequent recovery at 37°C
ed and treated as above. HSF1 was detected directly after HS while
various concentrations of doxorubicin for 48 h (B16F10) or 72 h
e untreated cells; mean values ± SD from three independent
Table 1 The IC50 values of various chemotherapeutics in mouse and human melanoma cells with different status
of HSF1
Doxorubicin, Vinblastine, Paclitaxel, Cisplatin, Bortezomib,
ng/ml nM nM μM nM
B16F10
Unmodified 10 ± 3,46 4,3 ± 0,71 19 ± 2,64 5,03 ± 1,88 9,73 ± 3,4
Neo 10,8 ± 3,3 3,6 ± 0,87 16 ± 2 6,47 ± 3,41 8,77 ± 1,97
hHSF1 31,5 ± 5,07* 3 ± 0,28 30,67 ± 5,03* 6,77 ± 1,78 10,8 ± 3,68
aHSF1 8,97 ± 1,76 3,13 ± 0,42 20,67 ± 5,03 6,63 ± 2,92 7,63 ± 1,86
hHSF1-DN 39 ± 1,41* 4,7 ± 1,1 29,67 ± 0,58* 6,9 ± 0,14 7,9 ± 1,65
WM793B
Unmodified 20,67 ± 5,77 7 ± 2,65 30,2 ± 5,37 5,6 ± 1,41 3,85 ± 0,07
Neo 17,83 ± 6,33 6,33 ± 1,6 27,47 ± 6,57 4,55 ± 1,34 3,65 ± 0,07
hHSF1 71,33 ± 3,06* 4,75 ± 0,07 58,2 ± 3,11* 5,4 ± 0,71 3,3 ± 0,63
aHSF1 25,33 ± 2,31 7,75 ± 2,47 41,6 ± 6,4 4,3 ± 1,56 3,7 ± 0,14
hHSF1-DN 75 ± 1,41* 5,4 ± 1,41 77 ± 4,24* 7,47 ± 4,1 3,55 ± 0,21
1205Lu
Unmodified 33,47 ± 2,54 2,375 ± 0,04 25 ± 5,55 6,93 ± 1,33 3,2 ± 0,85
Neo 31,13 ± 3,31 2,6 ± 0,96 19,37 ± 7,99 4,37 ± 0,51 3,15 ± 1,06
hHSF1 66 ± 11,31* 3,5 ± 0,14 52,67 ± 7,02* 6,93 ± 2,69 2,55 ± 0,07
aHSF1 24,8 ± 1,7 3,6 ± 1,13 22,33 ± 0,5 5,6 ± 1,64 3,15 ± 0,92
hHSF1-DN 54,5 ± 20,5* 4,67 ± 1,1 38 ± 2* 5,87 ± 1,01 3,65 ± 0,64
Asterisks indicate p < 0.05.
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than in control cells. In contrast, the IC50 value for cis-
platin, vinblastine or bortezomib was not changed due
to hHSF1 overexpression (Table 1). We have concluded
that overexpression of hHSF1 results in an enhanced
viability of cells treated specifically with doxorubicin or
paclitaxel.
Efflux of fluorescent dyes is more efficient and side
population is increased in cells overexpressing HSF1
To elucidate mechanisms of acquired doxorubicin resist-
ance of cells overexpressing hHSF1 we estimated accu-
mulation of the drug by flow cytometry. Cells were
treated with doxorubicin (1 μg/ml) for 30 minutes and
then the doxorubicin fluorescence was checked. Under
those conditions doxorubicin accumulation was lower in
hHSF1-transduced cells than in control cells, yet observed
differences did not reach the level of statistical significance
(Figure 2A, see also Additional file 3: Figure S2). The
intracellular accumulation of doxorubicin is dependent
on the activity of ABCB1 or other proteins belonging to
the ABC transporters family. Therefore, we assessed the
accumulation of a tracer dye eFluxx-ID™ Green Detec-
tion Reagent (Enzo Life Sciences). The reagent is a sub-
strate for three main ABC transporter proteins, ABCB1,ABCC1/ABCC2 and ABCG2 and can serve as an indica-
tor of these proteins’ activity in cells. We found that the
dye-specific fluorescence was significantly lower in cells
overexpressing hHSF1, and the most effective drug ef-
flux occured in hHSF1-WM793B cells (Figure 2B). This
indicates higher activity of ABC transporters in hHSF1-
overexpressing melanoma cells leading to more effective
drug efflux.
The enhanced ability to efflux of certain dyes such as
Hoechst 33342 [23] is a characteristic phenotypic feature
of certain kinds of cells, namely side population (SP)
cells. We examined the presence of SPs in B16F10,
WM793B and 1205Lu cells by staining them with Hoechst
33342 dye in order to generate a Hoechst blue-red profile
(see Additional file 4: Figure S3). As a control, verapamil
was added which blocks the activity of Hoechst 33342
transporters, and the SP fraction was defined as the dye-
free cell fraction diminished in the presence of verapamil.
A fraction of SP in control Neo cells ranged from 0.175%
to 0.28% of the whole assessed cell population, whereas
the number of SP cells was significantly increased in
cells overexpressing hHSF1 (>2 fold: an effect especially
well noticed in B16F10 line) compared to control cells
(Figure 2C). The obtained results suggest that HSF1
overexpression may contribute to the generation of SP
phenotype of melanoma cells.
Figure 2 Fluorescent dyes efflux is enhanced in melanoma cells
overexpressing HSF1. Intracellular fluorescence of doxorubicin (A)
and eFluxx-ID™ Green Detection Reagent (B) in hHSF1-overexpressing
cells is shown in relation to control (Neo) cells (C). The percentage
of dye-negative cells (side population, SP) following incubation
with Hoechst 33342 in the absence or presence of verapamil is
presented. Mean values ± SD from at least three experiments are
shown (asterisks indicate p < 0.05).
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enhance resistance to doxorubicin while expression of
dominant-negative HSF1 does
To further investigate the mechanism of HSF1-dependent
resistance of melanoma cells to doxorubicin we tested two
mutant forms of HSF1: constitutively active one and
dominant-negative one. The constitutively active form
(aHSF1) corresponds to the human HSF1 with a deletion
in a heat-responsive regulatory domain (RD; residues
221–315). Dominant-negative form (hHSF1-DN) corre-
sponds to the human HSF1 with a deletion in the C-
terminal transcriptional activation domain (residues
453–523) (see Additional file 1: Figure S1). It has been
previously shown that deletion of amino acids 221–315
conferred on HSF1 the ability to bind DNA and to in-
duce HSPs expression in the absence of heat shock
[6,7], while deletion of amino acids within C-terminal
domain led to DNA-binding activity of HSF1 without
the ability to activate HSPs expression during heatshock [19]. We established mouse (B16F10) and human
(WM793B and 1205Lu) cells overexpressing these mu-
tant forms of HSF1. The shorter mutant forms of HSF1
were present in the modified cells in addition to the longer
endogenous HSF1 form (Figure 3). Stably transfected cells
were tested for HSPs expression in the absence or after
heat shock. Increased expression of several HSP genes
(HSPH1, HSPB1, HSPA1) was detected in cells overex-
pressing aHSF1 already at physiological temperature. On
the other hand, induction of the same HSP genes was par-
tially blocked following hyperthermia in mouse B16F10
cells overexpressing hHSF1-DN (Figure 3A). In human
cells, introduction of hHSF1-DN was associated with a
slightly higher expression of some HSPs (HSPA1, HSPH1)
at physiological temperature, which suggested that intro-
duced dominant negative HSF1 could form heterotrimers
with endogenous HSF1 leading to basal transcriptional ac-
tivity [19,24]. However, in the presence of hHSF1-DN
hyperthermia-induced accumulation of HSPs was sup-
pressed in both mouse and human cells (Figure 3B). We
have concluded that overexpression of aHSF1 mimicked
transcriptional activity of HSF1 during stress conditions,
while hHSF1-DN was able to suppress strong induction of
HSF1-dependent HSP genes normally observed after heat
shock, plausibly by blocking the endogenous HSF1
binding.
Cells overexpressing mutant forms of HSF1 were
treated with several cytotoxic agents as described previ-
ously. Cell viability was determined by the MTT assay
and IC50 was calculated. We found that overexpression
of hHSF1-DN enhanced cell viability following treatment
with doxorubicin (Figure 3C, Table 1) or paclitaxel
(Table 1), as compared to control. The IC50 values for
doxorubicin or paclitaxel were around 2-fold higher in
cells overexpressing hHSF1-DN and full form of HSF1
(hHSF1) than those observed in control cells, either un-
modified or Neo. In contrast, aHSF1-overexpressing
cells were unable to confer doxorubicin or paclitaxel re-
sistance, and viability of these cells was the same as that
of control cells (Figure 3C, Table 1). The IC50 value of
cisplatin, vinblastine or bortezomib remained unchanged
even though the examined cells overexpressed mutant
forms of HSF1 (Table 1). We have concluded that HSF1-
associated resistance of melanoma cells treated with doxo-
rubicin or paclitaxel was not coupled to HSPs expression,
as cells overexpressing the transcriptionally active form of
HSF1 did not acquire resistance to these drugs despite ele-
vated level of HSPs.
Silencing of HSF1 expression in mouse melanoma B16F10
cells has no significant effect on the survival of cells
treated with doxorubicin
We aimed at down-regulating HSF1 expression to deter-
mine whether decreased level of HSF1 will reduce the
Figure 3 An increased resistance of melanoma cells to doxorubicin is not coupled with HSF1 transcriptional activity. A. Detection of
transcripts of HSF1 and HSP genes in B16F10, WM793B and 1205Lu cells containing either the empty vector (Neo) or HSF1 mutants. Where
indicated, cells were subjected to heat shock (HS) for 1 h at 42°C with subsequent recovery at 37°C for 30 minutes. B. Western blot detection of
HSF1 and HSPs in cells modified and treated as above. HSF1 was detected directly after HS while HSPs were detected after a 6-hour recovery.
C. Viability of cells treated with various concentrations of doxorubicin for 48 h (B16F10) or 72 h (WM793B and 1205Lu). Results of the MTT assay
are shown in relation to the untreated cells; mean values ± SD from three experiments are presented (asterisks indicate p < 0.05).
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siRNA sequences, complementary to 3′UTR (HSF1-1)
or to the coding sequence (HSF1-2) were stably intro-
duced into murine B16F10 cells (stable human cells with
silenced HSF1 were not obtained due to lethality). HSF1
and HSPs expression was analyzed by RT-PCR and
Western blot in control cells expressing scrambled shRNA
and in cells with HSF1-1 and HSF1-2 shRNAs before or
after heat shock (Figure 4A,B). Both HSF1-specific shRNA
sequences were able to reduce mRNA level and protein
level of HSF1. Down regulation of HSF1 expression was
connected with a significantly reduced inducibility of HSP
genes (Hsph1, Hsp90aa1, Hspa1 and Hspb1) following
hyperthermia; of note, shRNA complementary to 3′UTR
(HSF1-1) was more effective.
To determine the effect of HSF1 silencing on the sen-
sitivity of B16F10 cells to doxorubicin, cells expressingshRNAs described above were treated for 48 hours with
increasing concentrations of doxorubicin (5–40 ng/ml).
We observed that cell viability determined using MTT
assay was not strongly affected by HSF1 silencing, and
was only marginally lower than in the control cells
(Figure 4C).
The mRNA level of several ABC transporters is increased
in cells overexpressing HSF1 and its dominant negative
form
Increased efflux of drugs mediated by the ABC trans-
porters is the most commonly encountered mechanism
of drug resistance. We analyzed the expression of several
ABC transporters in melanoma cells having different HSF1
status. We selected ABCB1, ABCC1, ABCC2, ABCC5,
ABCB8, ABCD1 transporters, which were previously re-
ported to be involved in doxorubicin resistance [25,26]. In
Figure 4 HSF1 silencing does not influence doxorubicin
resistance in mouse melanoma B16F10 cells. A. Detection of
transcripts of Hsf1 and Hsp genes in cells expressing control
scrambled shRNA or HSF1-specific shRNAs (HSF1-1, HSF1-2). Where
indicated, cells were subjected to heat shock (HS) for 1 h at 42°C
with subsequent recovery at 37°C for 30 minutes. B. Western blot
detection of HSF1 and HSPs in cells expressing control scrambled
shRNA or HSF1-specific shRNAs (HSF1-1, HSF1-2). HSF1 was detected
directly after HS while HSPs were detected after 6 hours recovery.
C. Viability of cells treated with various concentrations of
doxorubicin for 48 h. Results of the MTT assay are shown in relation
to the untreated cells; mean values ± SD from three independent
experiments are presented.
Figure 5 Expression of several ABC transporters is increased in
cells overexpressing full HSF1 or its dominant negative form.
Changes in ABC transporter genes expression were estimated based
on semi-quantitative RT-PCR (after gel densitometry) in B16F10 cells
(A) or using quantitative RT-PCR in WM793B (B) and 1205Lu (C)
human cells. Fold changes were calculated in relation to expression
levels in control (Neo) cells (1.0 value represented by a horizontal
red line) after normalization against GAPDH gene expression. Results
represent mean values ± SD from three experiments.
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regulation of Abcb1b/ABCB1 gene transcription observed
in both mouse and human cells (Figure 5). Transcription
of other analyzed ABC genes (namely ABCB8, ABCC1,
ABCC2, ABCC5 and ABCD1) was significantly elevated in
human cells overexpressing hHSF1 (Figure 5B,C), but not
in mouse cells (data not shown). We could not confirmdifferences in ABC protein levels between control and
hHSF1-overexpressing cells due to unsatisfactory speci-
ficities of available antibodies, which showed substantial
cross-reactivity to other proteins.
The level of Abcb1b/ABCB1 mRNA in cells overex-
pressing hHSF1-DN, both mouse and human, was also
higher than in control Neo cells and cells overexpressing
aHSF1 form (Figure 5). Transcripts of some other ABC
transporters were more abundant in human cells overex-
pressing hHSF1-DN compared to control cells (Figure 5B,
C). When the level of Abcb1b gene transcript was tested
in B16F10 cells with silenced HSF1 we found its reduced
expression only in the case of shRNA complementary to
3′UTR (HSF1-1) (Figure 5A). We concluded that expres-
sion of ABC genes was significantly increased in cells
overexpressing hHSF1-DN form despite lack of direct
transcriptional effect on HSP genes. Importantly, cells
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for drug efflux (tested with eFluxx-IDTM Green Detection
Reagent; see Additional file 5: Figure S4). The obtained re-
sults suggest importance of HSF1 regulatory domain (ab-
sent in aHSF1 form) for enhanced ABC expression and
drug resistance.
Discussion
High levels of HSF1 and HSPs expression were observed
in a broad range of human tumors [27-30]. Moreover, it
has been shown that increased HSF1 expression is asso-
ciated with reduced survival of cancer patients. It is not
surprising as HSF1 modulates an entire network of cel-
lular functions that enable neoplastic transformation
[8,31]. However, the impact of HSF1 overexpression on
cell susceptibility to chemotherapy has not been studied
so far. Chemotherapy, a major modality of cancer treat-
ment, is effective initially in controlling the growth of
many sensitive tumors, but later it often fails due to the
development of resistance to the received drugs. Diverse
mechanisms are involved in the acquisition of drug re-
sistance by cancer cells. Understanding them is the key
to identify new possible treatments.
In the presented work, we screened the sensitivity of
mouse (B16F10) and human (WM793B and 1205Lu)
melanoma cells overexpressing HSF1 to different anti-
cancer drugs. We found that HSF1 overexpression had
no effect on the survival of cells treated with cisplatin,
vinblastine or bortezomib, while the survival of cells
treated with doxorubicin or paclitaxel was significantly
enhanced when compared to their parental wild-type
cells (or control cells containing the empty vector). Sur-
prisingly, we revealed that such selective resistance of
melanoma cells was not dependent on direct transcrip-
tional activity of HSF1 (and linked HSPs expression and
accumulation). Melanoma cells expressing transcription-
ally competent and constitutively active HSF1 mutant
characterized by an enhanced expression of HSPs did
not acquire resistance. On the other hand, HSF1 mutant
form with a deletion in the transcriptional activation do-
main was found to be as effective as overexpression of
wild-type HSF1.
The primary role of HSF1 is traditionally referred to
the regulation of HSP genes expression. It is generally
accepted that HSPs are the fundamental component of
cytoprotective reaction that enables somatic cells to sur-
vive exposure to harmful conditions. HSPs prevent protein
denaturation and/or processing of denatured proteins,
which limits accumulation of misfolded species [32,33].
Other mechanism of HSP-dependent cytoprotection in-
volves inhibition of apoptosis. Direct physical interactions
with apoptotic molecules were demonstrated for HSPA1,
HSPB1 and HSP90 [34,35]. Regardless of well-known cyto-
protective function of HSPs, its role in the effectiveness ofchemotherapy is not obvious. There are several reports
showing that up-regulation of HSP90, HSPA1 or HSPB1 is
associated with cell resistance to cisplatin or doxorubicin
[36-39]. Furthermore, the damage induced by doxorubicin
is more efficiently repaired following heat shock, which
correlates with nuclear translocation of HSPB1 and HSPA1
[40]. Also, it was reported that heat-induced carboplatin
resistance of p53-dependent hepatoma cells is mediated
by HSPA1 [41]. Nevertheless, there are several reports
demonstrating that activation of HSPs expression does
not enhance cancer cell survival in various types of neo-
plasia upon cisplatin, colchicine, 5-fluorouracil, actino-
mycin D or methotrexate treatments [42-46]. Moreover,
diminished HSPs expression resulting from HSF1 silen-
cing did not abrogate resistance of cervix carcinoma HeLa
cells to cisplatin [47]. Thus, it seems plausible that suscep-
tibility of cells to chemotherapeutics does not solely de-
pend on HSPs expression. The presence of HSPs could be
just a secondary effect of HSF1 activity, while mechanisms
of HSF1-dependent resistance of cancer cells to drugs
could be connected to its interactions with other proteins
and/or its impact (direct or indirect) on expression of
non-HSPs genes. If fact, it was already reported that HSF1
interacts with p53 and enhances p53-mediated transcrip-
tion [48] or regulates expression of ATG7 (autophagy-
related protein 7) [49]. Recent studies have shown that
although HSPs expression is important for the tumor
initiation [50], a network of genes regulated by HSF1 in
malignant cells is distinct from the transcriptional pro-
gram induced by heat shock [51].
In this report we show that enhanced resistance to
doxorubicin and paclitaxel is associated with enhanced
drug efflux. Most markedly, the ABC transporter sub-
strate eFluxx-ID Green Reagent was more effectively re-
moved from cells overexpressing HSF1. We found that
transcription of several ABC transporters was increased
not only in cells overexpressing HSF1 but also its dom-
inant negative form, while not the constitutively active
form. This finding suggests that enhanced expression of
ABC genes is not coupled directly to transcriptional ac-
tivity of HSF1. The expression of Abcb1b/ABCB1 gene
was mostly dependent on HSF1 in all three tested mel-
anoma cell lines. It has been previously demonstrated
that multidrug resistance of osteosarcoma U2-OS cells
and hepatoma HepG2 cells was mediated by HSF1-
dependent expression of the ABCB1 gene, but not by
HSPs expression [52]. Additionally, the transcriptional
activity of HSF1 has been required for enhanced expres-
sion of ABCB1 gene in HeLa cells [18]. Although HSE
(heat shock element) sequences are present in ABCB1
gene promoter [17], it was revealed that the mere binding
of HSF1 was not sufficient to transactivate the ABCB1 ex-
pression, as it was in the case of HSP genes [18,19]. Hence,
a plausible posttranscriptional mechanism of ABCB1 up-
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posed [52].
Different mechanisms explaining HSF1 influence on
ABC mRNAs up-regulation may be proposed. Our data
indicate that the HSF1 regulatory domain, which confers
repression at control temperature and heat inducibility
of HSF1 is required for this effect. It could be hypothe-
sized that HSF1 mediates, via its regulatory domain, the
activity of other transcription factors or that it affects
mRNA maturation or stability. Although a role for HSF1
in RNA processing has not been fully documented,
HSF1 incorporation into nuclear stress bodies, where
RNA splicing could take place, was reported [53]. Re-
cently, it was shown that HSF1 is involved in the regula-
tion of mRNA-binding protein ELAVL1 (HuR) which, in
turn, controls mRNA stability and/or translation of
many proteins involved in cancer [54]. In spite of HSF1-
dependent accumulation of Abc/ABC transcripts we did
not confirm the corresponding accumulation of ABC
proteins. However, our data confirm an enhanced drug
efflux, which is considered to be the most relevant indi-
cator of both expression of ABC transporters and its
molecular catalytic activity [55,56].
Conclusions
The results of our study indicate that melanoma cells with
HSF1 overexpression are more resistant to doxorubicin or
paclitaxel. Such HSF1-mediated drug resistance is not
dependent on HSPs accumulation but is rather associated
with increased drug efflux mediated by ABC transporters.
However, direct transcriptional activity of HSF1 is not ne-
cessary for increased ABC genes expression. We assume
that HSF1, but not HSF1-induced HSPs expression, is crit-
ical for the observed selectively enhanced drug resistance.Additional files
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